Field evaluation of a novel, rapid diagnostic assay, and molecular epidemiology of enterotoxigenic E. coli among Zambian children presenting with diarrhea.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
08 2022
Historique:
received: 29 01 2022
accepted: 22 07 2022
revised: 17 08 2022
pubmed: 6 8 2022
medline: 20 8 2022
entrez: 5 8 2022
Statut: epublish

Résumé

Enterotoxigenic Escherichia coli (ETEC) is one of the top aetiologic agents of diarrhea in children under the age of 5 in low-middle income countries (LMICs). The lack of point of care diagnostic tools for routine ETEC diagnosis results in limited data regarding the actual burden and epidemiology in the endemic areas. We evaluated performance of the novel Rapid LAMP based Diagnostic Test (RLDT) for detection of ETEC in stool as a point of care diagnostic assay in a resource-limited setting. We conducted a cross-sectional study of 324 randomly selected stool samples from children under 5 presenting with moderate to severe diarrhea (MSD). The samples were collected between November 2012 to September 2013 at selected health facilities in Zambia. The RLDT was evaluated by targeting three ETEC toxin genes [heat labile toxin (LT) and heat stable toxins (STh and STp)]. Quantitative PCR was used as the "gold standard" to evaluate the diagnostic sensitivity and specificity of RLDT for detection of ETEC. We additionally described the prevalence and seasonality of ETEC. The study included 324 participants, 50.6% of which were female. The overall prevalence of ETEC was 19.8% by qPCR and 19.4% by RLDT. The children between 12 to 59 months had the highest prevalence of 22%. The study determined ETEC toxin distribution was LT 28/321(9%), ST 18/321(6%) and LT/ST 16/321(5%). The sensitivity and specificity of the RLDT compared to qPCR using a Ct 35 as the cut-off, were 90.7% and 97.5% for LT, 85.2% and 99.3% for STh and 100% and 99.7% for STp, respectively. The results of this study suggest that RLDT is sufficiently sensitive and specific and easy to implement in the endemic countries. Being rapid and simple, the RLDT also presents as an attractive tool for point-of-care testing at the health facilities and laboratories in the resource-limited settings.

Sections du résumé

BACKGROUND
Enterotoxigenic Escherichia coli (ETEC) is one of the top aetiologic agents of diarrhea in children under the age of 5 in low-middle income countries (LMICs). The lack of point of care diagnostic tools for routine ETEC diagnosis results in limited data regarding the actual burden and epidemiology in the endemic areas. We evaluated performance of the novel Rapid LAMP based Diagnostic Test (RLDT) for detection of ETEC in stool as a point of care diagnostic assay in a resource-limited setting.
METHODS
We conducted a cross-sectional study of 324 randomly selected stool samples from children under 5 presenting with moderate to severe diarrhea (MSD). The samples were collected between November 2012 to September 2013 at selected health facilities in Zambia. The RLDT was evaluated by targeting three ETEC toxin genes [heat labile toxin (LT) and heat stable toxins (STh and STp)]. Quantitative PCR was used as the "gold standard" to evaluate the diagnostic sensitivity and specificity of RLDT for detection of ETEC. We additionally described the prevalence and seasonality of ETEC.
RESULTS
The study included 324 participants, 50.6% of which were female. The overall prevalence of ETEC was 19.8% by qPCR and 19.4% by RLDT. The children between 12 to 59 months had the highest prevalence of 22%. The study determined ETEC toxin distribution was LT 28/321(9%), ST 18/321(6%) and LT/ST 16/321(5%). The sensitivity and specificity of the RLDT compared to qPCR using a Ct 35 as the cut-off, were 90.7% and 97.5% for LT, 85.2% and 99.3% for STh and 100% and 99.7% for STp, respectively.
CONCLUSION
The results of this study suggest that RLDT is sufficiently sensitive and specific and easy to implement in the endemic countries. Being rapid and simple, the RLDT also presents as an attractive tool for point-of-care testing at the health facilities and laboratories in the resource-limited settings.

Identifiants

pubmed: 35930612
doi: 10.1371/journal.pntd.0010207
pii: PNTD-D-22-00127
pmc: PMC9385031
doi:

Substances chimiques

Bacterial Toxins 0
Enterotoxins 0
Escherichia coli Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0010207

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Braz J Infect Dis. 2011 Mar-Apr;15(2):132-7
pubmed: 21503399
J Clin Microbiol. 2006 Nov;44(11):3872-7
pubmed: 16943355
Clin Microbiol Rev. 2013 Oct;26(4):822-80
pubmed: 24092857
Lancet Glob Health. 2019 Mar;7(3):e321-e330
pubmed: 30784633
J Travel Med. 2011 Mar-Apr;18(2):121-5
pubmed: 21366796
Lancet Infect Dis. 2018 Nov;18(11):1165-1166
pubmed: 30266327
PLoS Negl Trop Dis. 2022 Jan 28;16(1):e0010180
pubmed: 35089927
Mem Inst Oswaldo Cruz. 2007 Nov;102(7):839-44
pubmed: 17992362
Clin Infect Dis. 2012 Dec;55 Suppl 4:S215-24
pubmed: 23169934
PLoS One. 2017 May 5;12(5):e0176882
pubmed: 28475640
Vaccine. 2021 Jul 13;39(31):4266-4277
pubmed: 33965254
J Clin Microbiol. 2013 Feb;51(2):472-80
pubmed: 23175269
Lancet Infect Dis. 2018 Nov;18(11):1229-1240
pubmed: 30266330
Braz J Microbiol. 2011 Jan;42(1):243-7
pubmed: 24031627
Trop Med Health. 2016 Nov 29;44:39
pubmed: 27942243
Lancet Infect Dis. 2018 Nov;18(11):1211-1228
pubmed: 30243583
Curr Infect Dis Rep. 2019 Mar 4;21(3):9
pubmed: 30830466
J Clin Microbiol. 2008 Mar;46(3):996-1004
pubmed: 18174300
Clin Microbiol Rev. 2005 Jul;18(3):465-83
pubmed: 16020685
Am J Trop Med Hyg. 2007 Sep;77(3):571-82
pubmed: 17827382
J Travel Med. 2017 Apr 01;24(suppl_1):S6-S12
pubmed: 28520997
Trop Med Infect Dis. 2021 Jan 16;6(1):
pubmed: 33467065
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Clin Infect Dis. 2016 May 1;62 Suppl 2:S175-82
pubmed: 27059353
PLoS Negl Trop Dis. 2022 Feb 7;16(2):e0010192
pubmed: 35130310

Auteurs

Suwilanji Silwamba (S)

Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia.

Obvious N Chilyabanyama (ON)

Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Fraser Liswaniso (F)

Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Caroline C Chisenga (CC)

Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Roma Chilengi (R)

Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Gordon Dougan (G)

Cambridge Institute for Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom.

Geoffrey Kwenda (G)

Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia.

Subhra Chakraborty (S)

Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States of America.

Michelo Simuyandi (M)

Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH